Protease chain reactions for molecular analysis of cancer markers

用于癌症标志物分子分析的蛋白酶链反应

• 批准号: 9107423
• 负责人: Biao Ruan
• 金额: $ 49.49万
• 依托单位: POTOMAC AFFINITY PROTEINS, LLC
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-19 至 2018-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9107423
• 关键词: Analog Computers; Antibodies; Binding; Biological Assay; Cancer Detection; Characteristics; Cleaved cell; Complex; DNA amplification; Detection; Development; Elements; Engineering; Enzymes; Generations; Goals; Health; Hour; IL6 gene; Interstitial Collagenase; Logic; Measures; Molecular; Molecular Analysis; Optics; Output; Peptide Hydrolases; Phase; Plant Resins; Polymerase Chain Reaction; Process; Protease Inhibitor; Proteins; Reaction; Reagent; Sepharose; Signal Transduction; Technology; Testing; Time; Transducers; antibody conjugate; base; cancer biomarkers; cancer prevention; improved; inhibitor/antagonist; instrument; molecular marker; nano; novel; sensor

DESCRIPTION (provided by applicant): Our objective is to develop a Protease Chain Reaction technology (ProCR) that will enable ultra- sensitive and highly-quantitative detection of cancer markers. The basic element of a protease chain reaction is a protease-inhibitor complex. The protease is inactive when bound to the inhibitor but, once freed, is capable of cleaving the inhibitor and releasing additional free protease. A trace of free protease initiates the chain reaction and eventually causes the release of all protease from the inhibitory complex. The lag time preceding the full release of protease is determined by the initial concentration of free protease. The Phase I project developed a first-generation of self-amplifying complexes that form the core of the ProCR detection technology. All Phase I milestones were significantly exceeded. In Phase II we will develop powerful molecular sensors based on self- amplifying complexes. A sensor consists of three elements: 1) a sensing element that responds to the presence of an analyte; 2) the processing/computational element that amplifies and quantifies the signal from the detection element; and 3) the transducer element that produces an optical signal. Through this combination, extremely sophisticated enzymatic sensors will be built to detect cancer markers. Accordingly the three experimental Aims are to: 1) Engineer sensing elements; 2) Engineer enhanced processing/computational elements; and 3) Engineer signaling components. Fundamentally, a protein chain reaction is a powerful analogue computer with two key characteristics that greatly facilitate the detection of target molecules. 1) It can convert th concentration of a specific target molecule into a time signature. 2) It can create enormous signal amplification, analogous to the amplification of DNA by a polymerase chain reaction (PCR). Thus detection is enabled because the final observable signal produced by a target molecule can be very large and the time lag until onset of the signal is precisely correlated with the concentration of target molecule. The long term goal is to develop protease-inhibitor complexes as enzymatic nano-processors which can be combined to detect multiple signals and to control output with multiple logic gates.

描述（由申请人提供）：我们的目标是开发一种蛋白酶链反应技术（ProCR），该技术将能够超灵敏和高定量地检测癌症标志物。蛋白酶链式反应的基本要素是蛋白酶抑制剂复合物。当与抑制剂结合时，蛋白酶是无活性的，但一旦被释放，它能够切割抑制剂并释放额外的游离蛋白酶。微量的游离蛋白酶启动链式反应，最终导致所有蛋白酶从抑制复合体中释放出来。蛋白酶完全释放前的滞后时间由游离蛋白酶的初始浓度决定。第一阶段项目开发了第一代自扩增复合物，构成了ProCR检测技术的核心。所有第一阶段的里程碑都被显著超越。在第二阶段，我们将开发基于自扩增复合物的强大分子传感器。传感器由三个元件组成：1)对分析物的存在作出响应的传感元件；2)对来自检测元件的信号进行放大和量化的处理/计算元件；3)产生光信号的换能器元件。通过这种结合，极其复杂的酶传感器将被用来检测癌症标志物。因此，三个实验目标是：1)工程传感元件；2)工程师增强处理/计算元素；3)工程信号组件。从根本上说，蛋白质链式反应是一个强大的模拟计算机，具有两个关键特征，极大地促进了目标分子的检测。1)它可以将特定靶分子的浓度转化为时间特征。2)它可以产生巨大的信号扩增，类似于通过聚合酶链反应（PCR）扩增DNA。因此，检测是可行的，因为目标分子产生的最终可观察信号可能非常大，并且直到信号开始的时间滞后与目标分子的浓度精确相关。长期目标是开发蛋白酶抑制剂复合物作为酶的纳米处理器，它可以结合起来检测多个信号并通过多个逻辑门控制输出。